MetaADEDB 2.0 @ LMMD
Vinorelbine
(CILBMBUYJCWATM-LNLXBTRNSA-N)
Structure
SMILES
O[C@H]([C@H](C(=O)O)O)C(=O)O.O[C@H]([C@H](C(=O)O)O)C(=O)O.CCC1=C[C@H]2CN(C1)Cc1c3ccccc3[nH]c1[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N([C@@H]1[C@@]32CCN2[C@H]3[C@@](CC)(C=CC2)[C@H]([C@]1(O)C(=O)OC)OC(=O)C)C
Molecular Formula:
C53H66N4O20
Molecular Weight:
1079.110
Log P:
0.4492
Hydrogen Bond Acceptor:
23
Hydrogen Bond Donor:
10
TPSA:
363.99
CAS Number(s):
125317-39-7; 1217449-57-4
Synonym(s)
1.
Vinorelbine
2.
5'-Nor-anhydrovinblastine
3.
KW 2307
4.
KW-2307
5.
Navelbine
6.
Vinorelbine Tartrate
7.
5' Nor anhydrovinblastine
8.
KW2307
External Link(s)
MeSHD000077235
PubChem Compound45055483
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NeutropeniaFAERS: 18US FAERS
2Neutropenic infectionFAERS: 6US FAERS
3HaematotoxicityFAERS: 5US FAERS
4ConstipationFAERS: 4US FAERS
5FatigueFAERS: 4US FAERS
6Febrile NeutropeniaFAERS: 4US FAERS
7Abdominal PainFAERS: 3US FAERS
8Acute Coronary SyndromeFAERS: 3US FAERS
9BronchospasmFAERS: 3US FAERS
10Burning sensationFAERS: 3US FAERS
11NauseaFAERS: 3US FAERS
12DehydrationFAERS: 2US FAERS
13Diffuse alveolar damageFAERS: 2US FAERS
14Dyspnoea exacerbatedFAERS: 2US FAERS
15Emotional distressFAERS: 2US FAERS
16FibrosisFAERS: 2US FAERS
17General physical health deteriorationFAERS: 2US FAERS
18HypotensionFAERS: 2US FAERS
19PneumoniaFAERS: 2US FAERS
20PneumonitisFAERS: 2US FAERS
21Pulmonary EmbolismFAERS: 2US FAERS
22Skin toxicityFAERS: 2US FAERS
23SyncopeFAERS: 2US FAERS
24TachycardiaFAERS: 2US FAERS
25ThrombocytopeniaFAERS: 2US FAERS
26Angina PectorisFAERS: 1US FAERS
27AstheniaFAERS: 1US FAERS
28ChillsFAERS: 1US FAERS
29CholelithiasisFAERS: 1US FAERS
30Coronary Artery DiseaseFAERS: 1US FAERS
31DiverticulitisFAERS: 1US FAERS
32ErythemaFAERS: 1US FAERS
33HypothyroidismFAERS: 1US FAERS
34Intestinal ObstructionFAERS: 1US FAERS
35Malignant neoplasm progressionFAERS: 1US FAERS
36NeuralgiaFAERS: 1US FAERS
37NeuropathyFAERS: 1US FAERS
38Oral candidiasisFAERS: 1US FAERS
39Posterior reversible encephalopathy syndromeFAERS: 1US FAERS
40ScabFAERS: 1US FAERS
41SepsisFAERS: 1US FAERS
42ThrombophlebitisFAERS: 1US FAERS
43VIIth nerve paralysisFAERS: 1US FAERS
44VomitingFAERS: 1US FAERS
45White blood cell count decreasedFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.